Pfizer disappoints in first quarter earnings, facing several headwinds

Pfizer (PFE) reported mixed archetypal 4th net Tuesday, arsenic the institution struggles to summation capitalist involvement successful its near-term pipeline amid a volatile macro situation successful the markets.

Pfizer reported adjusted net per stock (EPS) of 92 cents, beating Wall Street expectations of 66 cents per share. Revenue came successful astatine $13.7 billion, compared to statement of $14 billion.

The banal was up little than 1% successful pre-market trading Tuesday.

"We continued to execute with absorption and subject against our strategical priorities, including strengthening our R&D enactment and driving improved productivity. With the underlying spot of our business, we judge we tin beryllium agile successful navigating an uncertain and volatile outer environment," CEO Albert Bourla said successful a connection Tuesday.

Pfizer is 1 of the large-cap pharma companies successful absorption for investors arsenic it faces patent cliffs for apical blockbusters by the extremity of the decade. Investors person been waiting and watching arsenic COVID-19 revenues wane for the institution to right-size operations and find caller products successful its pipeline — some interior and acquired — to capable a $17 cardinal gross hole.

Bourla has antecedently said his flurry of deals successful the caller past, including the $43 cardinal for Seagen and its oncology pipeline, were executed to capable that gross hole. One cause alone, Padcev, is expected to adhd $3.1 cardinal annually. In 2024, it contributed $1.6 billion.

One anticipation had been the company's introduction into the obesity space, dominated by Eli Lilly (LLY) and Novo Nordisk (NVO). Pfizer had been viewed arsenic 1 of the cardinal contenders successful the near-term for Lilly and its oral mentation of the value nonaccomplishment drugs, which are presently successful injectable form. But this month, Pfizer had to halt its precocious signifier proceedings owed to a liver wounded successful 1 patient.

Pfizer reaffirmed its 2025 outlook of $61 to $64 cardinal successful gross and adjusted net per stock of $2.80 to $3.

Anjalee Khemlani is the elder wellness newsman astatine Yahoo Finance, covering each things pharma, insurance, attraction services, integer health, PBMs, and wellness argumentation and politics. That includes GLP-1s, of course. Follow Anjalee arsenic AnjKhem connected societal media platforms X, LinkedIn, and Bluesky @AnjKhem.

Click present for in-depth investigation of the latest wellness manufacture quality and events impacting banal prices